EvoDevo, published by BMC, is a premier open-access journal dedicated to the fields of Developmental Biology, Ecology, Evolution, Behavior and Systematics, and Genetics. With an impressive Q1 ranking in its category for 2023, EvoDevo stands out as a significant resource for researchers, professionals, and students seeking to explore the intricate relationships between evolutionary processes and developmental mechanisms. Since its inception in 2010, this UK-based journal has provided a platform for innovative research and insights, boasting rigorous peer-review standards that ensure high-quality publications. With the E-ISSN of 2041-9139 and a commitment to freely accessible research, EvoDevo is positioned at the forefront of scientific discourse, making vital contributions to our understanding of biological complexities. As the journal converges years from 2010 to 2024, it serves as a cornerstone for knowledge dissemination, inspiring future research trajectories in evolutionary developmental biology.

GENES BRAIN AND BEHAVIOR is a leading journal published by Wiley that focuses on the intricate interplay between genetic factors and behavioral neuroscience. With a robust ISSN of 1601-1848 and an E-ISSN of 1601-183X, this journal serves as a premier platform for innovative research that spans across multiple fields including genetics, neurology, and behavioral neuroscience. Recognized for its significant impact with a 2023 categorization of Q1 in Behavioral Neuroscience and Q2 in both Genetics and Neurology, GENES BRAIN AND BEHAVIOR asserts itself as an influential resource for scholars, practitioners, and students alike, facilitating the advancement of knowledge in these dynamic areas. Its Scopus rankings underscore its prominence—ranking #18 in Behavioral Neuroscience and #45 in Neurology, placing it in the top percentiles among its peers. Although not an open-access journal, the rigorous peer-review process ensures high-quality publications, pivotal for those pursuing cutting-edge research and applications. With a history of convergence from 2002 to 2024, this journal continues to foster academic dialogue and discovery in the ever-evolving landscape of brain and behavioral studies.

BEHAVIOR GENETICS is a leading peer-reviewed journal published by Springer, dedicated to advancing the field of behavioral genetics through the dissemination of original research and comprehensive reviews. With its foundation dating back to 1970, the journal has established itself as a crucial forum for scientists studying the interplay between genetic factors and behavior, addressing a diverse range of topics from animal behavior to human psychology. Currently, BEHAVIOR GENETICS holds prestigious rankings with a Q1 quartile in Ecology, Evolution, Behavior and Systematics, and Q2 rankings in both Genetics and Clinical Genetics, as of 2023. This positions the journal among the top tier of scholarly publications, with significant impact reflected in its Scopus ranking across various categories. Researchers, professionals, and students can explore valuable insights and opportunities for collaboration in this vibrant field, although it is noteworthy that the journal offers standard access options. As a valuable resource for cutting-edge discoveries, BEHAVIOR GENETICS continues to foster a deeper understanding of the genetic influences on behavior, making it essential reading for anyone invested in behavioral research.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

NEUROGENETICS is a distinguished journal published by SPRINGER, focusing on the intersection of genetics and neuroscience. With its ISSN 1364-6745 and E-ISSN 1364-6753, this journal has been a vital resource in the fields of cellular and molecular neuroscience and genetics since its establishment in 1997. As of 2023, it is ranked Q3 in Cellular and Molecular Neuroscience and Q2 in both Genetics and Clinical Genetics, reflecting its growing influence and importance in these areas. Although not an open-access journal, it provides significant insights and research findings that contribute to advancing our understanding of genetic influences on neural function and disease. Based in Germany with an address at ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES, NEUROGENETICS serves as a crucial platform for researchers, professionals, and students alike to explore innovative studies that are essential for the future of neuroscience and genetics. With its continuous commitment to high-quality research, the journal aims to foster collaboration and knowledge dissemination among the scientific community.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

The Journal of Genetics and Genomics, published by SCIENCE PRESS in China, stands as a significant contributor to the fields of Genetics and Molecular Biology. With an ISSN of 1673-8527 and E-ISSN 1873-5533, this esteemed journal has achieved a remarkable reputation, holding a prestigious Q1 ranking in both Genetics and Molecular Biology as of 2023. This journal not only showcases pioneering research but also fosters vital discussions on contemporary challenges and innovations within genomic sciences. As part of its commitment to facilitating scientific advancement, the journal encompasses a range of research articles, reviews, and short communications, all aiming to illuminate the complexities of genetic structures and functions from 2007 to 2024. Researchers, professionals, and students alike are encouraged to engage with its content, which ranks favorably in Scopus—placing it within the top tier of its categories. Join the community of academic excellence and explore the latest findings that shape our understanding of genomics.

GENOME is a leading peer-reviewed journal published by Canadian Science Publishing, dedicated to advancing the field of genetics, biotechnology, and molecular biology. With a strong commitment to disseminating high-quality research, GENOME has earned a reputable spot in the academic community, boasting a Q2 classification in Biotechnology and Medicine (miscellaneous), and a Q3 rank in Genetics and Molecular Biology for 2023. The journal, identified by its ISSN 0831-2796 and E-ISSN 1480-3321, publishes innovative studies that span from 1987 to 2024, ensuring a rich historical context while addressing contemporary challenges in the field. Researchers and professionals are encouraged to contribute and engage with content that shapes the landscape of genetic research. Although the journal does not currently provide open access, it remains a vital resource for those committed to the exploration of genomic sciences, making it an essential read for both seasoned researchers and students alike.

The EUROPEAN JOURNAL OF HUMAN GENETICS, published by SpringerNature, stands as a preeminent platform in the field of genetics and clinical genetics. Established in 1993, this prestigious journal, with an ISSN of 1018-4813 and an E-ISSN of 1476-5438, has consistently maintained its position in the Q1 quartile for both Genetics and Clinical Genetics categories as of 2023, reflecting its significant contributions to the field. Its impact is further underscored by its impressive Scopus rankings, placing it in the 92nd percentile among clinical genetics journals. The journal aims to disseminate cutting-edge research, case studies, and reviews that advance our understanding of human genetics, promoting collaboration and innovation among researchers, professionals, and students alike. While it does not currently offer open access, the journal provides substantial value through its rigorous peer review process and commitment to quality. As it continues to shape the future of genetic research through 2024 and beyond, the EUROPEAN JOURNAL OF HUMAN GENETICS remains an essential resource for those dedicated to exploring the complexities of human heredity.